Last reviewed · How we verify
Extension Period(JW0201) — Competitive Intelligence Brief
phase 3
Ophthalmology
Small molecule
Live · refreshed every 30 min
Target snapshot
Extension Period(JW0201) (Extension Period(JW0201)) — JW Pharmaceutical. Extension Period (JW0201) is a drug that extends the duration of action of a biologic.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Extension Period(JW0201) TARGET | Extension Period(JW0201) | JW Pharmaceutical | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Extension Period(JW0201) CI watch — RSS
- Extension Period(JW0201) CI watch — Atom
- Extension Period(JW0201) CI watch — JSON
- Extension Period(JW0201) alone — RSS
Cite this brief
Drug Landscape (2026). Extension Period(JW0201) — Competitive Intelligence Brief. https://druglandscape.com/ci/extension-period-jw0201. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab